Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
BioSpecifics Technologies Corp is a biotechnology business based in the US. BioSpecifics Technologies shares (BSTC) are listed on the PINK and all prices are listed in US Dollars. BioSpecifics Technologies employs 7 staff and has a trailing 12-month revenue of around USD$36.6 million.
|52-week range||USD$42 - USD$88.8|
|50-day moving average||USD$88.4248|
|200-day moving average||USD$69.2992|
|Wall St. target price||USD$88.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$2.36|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
|1 week (2021-01-08)||N/A|
|1 month (2020-12-15)||N/A|
|3 months (2020-10-16)||-100.00%|
|6 months (2020-07-17)||-100.00%|
|1 year (2020-01-17)||-100.00%|
|2 years (2019-01-18)||-100.00%|
|3 years (2018-01-18)||-100.00%|
|5 years (2016-01-15)||-100.00%|
Valuing BioSpecifics Technologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioSpecifics Technologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioSpecifics Technologies's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, BioSpecifics Technologies shares trade at around 38x recent earnings.
BioSpecifics Technologies's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.36. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioSpecifics Technologies's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioSpecifics Technologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$23.6 million.
The EBITDA is a measure of a BioSpecifics Technologies's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$36.6 million|
|Operating margin TTM||64.76%|
|Gross profit TTM||USD$38.2 million|
|Return on assets TTM||11.58%|
|Return on equity TTM||0%|
|Market capitalisation||USD$650.2 million|
TTM: trailing 12 months
There are currently 74,067 BioSpecifics Technologies shares held short by investors – that's known as BioSpecifics Technologies's "short interest". This figure is 22.5% up from 60,464 last month.
There are a few different ways that this level of interest in shorting BioSpecifics Technologies shares can be evaluated.
BioSpecifics Technologies's "short interest ratio" (SIR) is the quantity of BioSpecifics Technologies shares currently shorted divided by the average quantity of BioSpecifics Technologies shares traded daily (recently around 217844.11764706). BioSpecifics Technologies's SIR currently stands at 0.34. In other words for every 100,000 BioSpecifics Technologies shares traded daily on the market, roughly 340 shares are currently held short.
However BioSpecifics Technologies's short interest can also be evaluated against the total number of BioSpecifics Technologies shares, or, against the total number of tradable BioSpecifics Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioSpecifics Technologies's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 BioSpecifics Technologies shares in existence, roughly 10 shares are currently held short) or 0.0119% of the tradable shares (for every 100,000 tradable BioSpecifics Technologies shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioSpecifics Technologies.
Find out more about how you can short BioSpecifics Technologies stock.
We're not expecting BioSpecifics Technologies to pay a dividend over the next 12 months.
BioSpecifics Technologies's shares were split on a 2:1 basis on 21 April 1992. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your BioSpecifics Technologies shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for BioSpecifics Technologies shares which in turn could have impacted BioSpecifics Technologies's share price.
Over the last 12 months, BioSpecifics Technologies's shares have ranged in value from as little as $42 up to $88.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while BioSpecifics Technologies's is 0.2383. This would suggest that BioSpecifics Technologies's shares are less volatile than average (for this exchange).
BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware. As of December 1, 2020, BioSpecifics Technologies Corp. operates as a subsidiary of Endo International plc.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.